JOHNSON & JOHNSON

Johnson & Johnson insider buys reveal confidence in the company’s long‑term value and robust pipeline, highlighting Pinto Daniel E’s $646 M DSU purchase and future clinical prospects.

Johnson & Johnson insider trades reveal a sharp buy‑low, sell‑high strategy, offering insight into long‑term confidence and short‑term liquidity decisions.

J&J CEO Duato Joaquin’s recent $32 M insider sale shows disciplined, low‑impact trading—no signs of distress, just routine portfolio rebalancing.

Explore how Johnson & Johnson’s executive Wengel Kathryn E’s round‑trip trade signals liquidity moves, not strategic bets, and what it means for investors.

Insider buying of J&J’s DSUs signals confidence in its stable dividend and growing oncology pipeline—proof that even defensive names can spark upside.

Insider sales reveal routine portfolio moves, not a confidence loss—J&J’s Kenvue spin‑off, tech‑driven specialty strategy, and robust cost cuts keep growth on track.

Johnson & Johnson CEO Duato Joaquin sells 100k shares—exploring the motives, market sentiment, and what this means for investors and the company’s future.